You are here: Industry Insights > MS

News List

Recommendations Developed for Pediatric Multiple Sclerosis Trials drugs
June 03, 2019
Recommendations Developed for Pediatric Multiple Sclerosis Trials.
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians worldpharmanews
May 08, 2019
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians.
Simple blood test may predict MRI disease activity in MS europeanpharmaceuticalreview
May 05, 2019
A blood test to monitor a nerve protein in the blood of people with multiple sclerosis may help predict whether disease activity is flaring up…
Significant Number of Referred Patients Misdiagnosed With MS drugs
April 28, 2019
Nearly one in five patients referred to a multiple sclerosis specialty center are misdiagnosed, according to a study published in the May issue of Multiple Sclerosis and Related Disorders.
MS Pharma Acquires Genepharm contractpharma
April 17, 2019
Expands MS Pharma's geographic footprint, and complements its existing chronic disease portfolio...
EMA recommends temporarily restricting Lemtrada use in MS pharmatimes
April 16, 2019
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has started a ……
Contributors to Delay of Multiple Sclerosis Diagnosis ID'd drugs
February 27, 2019
First symptoms and disease type are contributors to delays in multiple sclerosis (MS) diagnosis, according to a study recently published in the Multiple Sclerosis Journal.....
Correcting minority underrepresentation in MS clinical trials europeanpharmaceuticalreview
January 03, 2019
Minority unerrepresentation in clinical trials for drugs to treat MS has led to doctors being unable to make informed decisions when prescribing…
Roche's Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS pharmafile
November 20, 2018
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in the treatment of relapsing
Sanofi teams up with Denali in $1.125bn neurological and inflammatory development deal pharmafile
November 19, 2018
Sanofi has sealed the deal with Denali Therapeutics to leverage the latter’s small molecule candidates in the development of new therapies to tackle a variety of neurological

Previous page 1 2 3 4 5 6 7 8 9 Next page